Coleman et al. / MSKCC developed a vascular-targeted therapy for bladder cancer. Padeliporfin is illuminated with the Modulight’s ML7710 laser, resulting in selective ablation of bladder tumors, without harming the healthy bladder tissue.
Modulight Spotlights: LASER-SHARP RESEARCH – March 2025 Read More »
A. Lepland and the teams at University of Tartu, Estonia and Veneto Institute of Oncology, Italy, developed a new immunotherapy for triple negative breast cancer, using Modulight ML6000-series laser. Tumor growth slowed down and the cancer’s spreading to the lungs was suppressed.
Modulight Spotlights: LASER-SHARP RESEARCH – February 2025 Read More »
Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable
ML7710 for photoactivated treatment of lung cancer Read More »
Introduction to light-controlled drug delivery systems Study description It is important that light-triggered liposomes efficiently release their contents, while the liposome stability should be maintained in the absence of laser light. The aim of this study is to determine how liposomal stability and drug release are affected by liposomal formulation. Indocyanine green was used as the light-sensitizing compound
Light-induced drug delivery with indocyanine green liposomes Read More »
Presented in: SPIE BIOS 2021 Authors: Zoe Ylöniemi, Johannes Kivelä, Elias Kokko, Robert Perttilä, Visa Kaivosoja, Lasse Orsila, Petteri Uusimaa
Published in: Nanoscale Authors: Akbar Samadi, Henrik Klingberg, Liselotte Jauffred, Andreas Kjær, Poul Martin Bendix, Lene B. Oddershede
